ACP-105
Muscle & Strength · SARM
Tier D
Bottom line
Read Off Label grades ACP-105 as D (3.3/10) based on very weak evidence, unclear benefit magnitude, and a unclear-risk safety profile.
Obscure SARM with minimal human exposure.
Typical use: Typical illicit: 5-15 mg/day PO — NOT FDA-approved; gray market; banned sport.
What this is
Obscure SARM with minimal human exposure. Acadia stopped development years ago. Sold by research chemical vendors with standard SARM pitch despite absence of efficacy or safety data in humans.
Mechanism
Non-steroidal partial AR agonist; developed by Acadia Pharmaceuticals originally for cognitive indications in hypogonadism; tissue-selective profile claimed
Dose & route
Typical illicit: 5-15 mg/day PO
Citations
- https://pubmed.ncbi.nlm.nih.gov/17444687/
- https://patents.google.com/patent/US7214690B2/en
- https://pubmed.ncbi.nlm.nih.gov/29378245/
Links go to the source. If a link is dead or you want something re-checked, let me know.
Common questions
- Does ACP-105 work?
- Read Off Label rates the evidence for ACP-105 as Very Weak and the benefit magnitude as unclear, producing an overall grade of D (3.3/10). Obscure SARM with minimal human exposure.
- Is ACP-105 safe?
- ACP-105 has a unclear risk profile in published human data. Legal status: NOT FDA-approved; gray market; banned sport. This is not medical advice — see the disclaimer.
- What is the typical dose for ACP-105?
- Typical illicit: 5-15 mg/day PO
- How does ACP-105 work?
- Non-steroidal partial AR agonist; developed by Acadia Pharmaceuticals originally for cognitive indications in hypogonadism; tissue-selective profile claimed
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.